Pathway of Research to Evaluation of Dose-Individualised Cancer Therapy: Development of a national individualised cancer-dosing program to both generate evidence and implement existing evidence on algorithms for dosing targeted and non-targeted chemotherapy

The PREDICT Program is funded by a Cancer Council NSW Pathways to a cancer free future grant. $1,961,951.80 over 5 years.

The aim of the program is to develop a personalised chemotherapy dosing system for cancer patients to improve quality of life, reduce side effects and increase chance of survival.

Current chemotherapy dosing is imprecise and not personalised. It is estimated that 20-30% of patients receiving chemotherapy will receive a dose that is too high for them, and 20-30% will receive a dose lower than what is needed for optimal effectiveness. By monitoring chemotherapy levels early in treatment, clinicians will be able to adjust doses to achieve the ideal blood level. This will lead to direct and significant benefits for patients across wide population groups including enabling greater accessibility for rural and remote patients.

Chief Investigators involved in the PREDICT Program include:

Professor Jennifer Martin - University of Newcastle

Professor Stephen Ackland - University of Newcastle

Professor Howard Gurney - Macquarie University

Professor Paul de Souza - University of Western Sydney

Professor Michael Michael - University of Melbourne

Professor Alan Boddy - University of South Australia

Professor Paul Scuffham - Griffith University

Dr Stephanie Reuter Lange - University of South Australia

Dr Peter Galettis - University of Newcastle

Professor Ian Olver - University of South Australia


  • Pathology Request Form (available soon)
  • Adverse Events Table (available soon)
  • PREDICT Terms of Reference (available soon)
  • Application for Affiliate Membership (available soon)

For more information contact: Jo Knight